Insights
Germany’s drug-pricing dilemma: Why Europe’s pivotal market holds the key to the MFN debate
25 June 2026
Much of the Most-Favoured-Nation debate asks whether the United States can persuade other countries to pay more for medicines. Germany is the market where that question is hardest to answer and where it matters most.
The cost of inaction on LDL cholesterol
24 June 2026
This Insight is based on the WHA79 panel discussion “Lowering Cholesterol, Increasing Impact: The Case for Earlier Action to Address the CV Epidemic”, co-organised by OHE and MSD, at the World Health Assembly in Geneva, May 2026.
One Europe, one assessment? Unpacking the European Joint Clinical Assessment
28 May 2026
As the first EU Joint Clinical Assessment reports approach, national HTA systems across Europe are already adapting to a new era of coordinated clinical evaluation.
Two numbers, one decision: making climate-health valuation usable across sectors
18 May 2026
An OHE insight, ahead of OHE’s participation in the Health Diplomacy House panel at the 79th World Health Assembly (Geneva, 21 May 2026).
Valuing patient and carer time in HTA: equity and opportunity cost
15 May 2026
We address two criticisms of valuing patient and carer time in HTA: that it would displace health outcomes by misallocating a fixed budget, and that it would introduce inequities based on individual productivity or income. We argue that patient and carer time are vital inputs to healthcare, and that ignoring them reduces rather than improves both efficiency and fairness.
Is the revised Congressional Budget Office model of new drug development fit for purpose?
6 May 2026
As U.S. drug-pricing policy changes accelerate, policymakers need reliable ways to understand how reduced pharmaceutical revenues might affect R&D incentives, but the Congressional Budget Office’s (CBO) revised simulation model of new drug development remains too simplified and insufficiently validated to guide real-world decisions.
Around the World in HTAs: Japan – An algorithmic approach to containing costs
14 April 2026
Japan’s health technology assessment (HTA) system uses algorithmic drug pricing and cost-effectiveness analysis to manage rising healthcare costs while maintaining universal access and innovation.
Seven reflections on the UK EQ-5D-5L value set – and what comes next
30 March 2026
The long-awaited UK EQ-5D-5L value set has been published, marking a key moment for health technology assessment. Its adoption by NICE is set to shape how health-related quality of life is valued, raising important questions for future HTA decisions.
Europe’s pharmaceutical policy choices – And what the United States stands to learn
18 March 2026
A recent policy discussion on Capitol Hill hosted by We Work For Health examined the lessons the United States might draw from Europe’s experience with pharmaceutical pricing and innovation. As a participant, my key takeaways focused on understanding the trade-offs underpinning EU and UK drug pricing policy and the broader impact on innovation for both sides of the Atlantic.